However, travelers often present with insufficient time for the standard HBV vaccine schedule (SVS). We examined seroprotection against HBV following an alternative two-visit vaccination schedule (TVS) with currently available vaccine products, and completion rates with this TVS. Methods. A retrospective cohort study was conducted in three travel clinics in British Columbia, Canada. Adults ≥20 years old traveling to an HBV-endemic country, and unable to complete the standard or rapid HBV vaccination schedule before departure, were offered a TVS that consisted of a double dose of HBV vaccine at day 0, followed by a single dose in 4 to 12 months. Immunity to HBV [anti-HBV surface antigen (HBs) ≥10 mIU/mL] was determined 1 to 6 months following the final dose of HBV vaccine. Logistic regression modeling was used to assess correlates of seroprotection. We also determined completion rate with this TVS at two clinics. Results. In total, 117 participants (age range, 21-81 years, median age 57) met the inclusion criteria. Of these, 97 (82.9%) were immune after the TVS. Immunity was demonstrated in 93.1% of patients <50 years old and 79.5% of patients ≥50 years old. Increasing age was associated with reduced odds of developing immunity to HBV using the TVS [adjusted odds ratio = 0.954, 95% confidence interval (CI): 0.904, 1.008]. The completion rate of the TVS was 32.6% over a 12-month period. Completion rates varied between clinics (23.5% vs 48.4%, p < 0.001), suggesting that clinic-specific follow-up policies were important. Conclusion. Seroprotection with completion of this TVS was similar to or exceeded that published in the literature for the SVS by age. However, even with a TVS, completion rates were low, underscoring the importance of follow-up. Further research is needed to determine whether travelers are protected prior to completion of this TVS.
H epatitis B virus (HBV) is a significant global health burden; more than 300 million people worldwide are infected with HBV and an estimated 1 million deaths result from HBV-related illness each year. 1 HBV infection remains highly or moderately endemic in countries in Asia, Africa, South America, the Middle East, and Eastern Europe. 2 Presented at 8th Annual Family Medicine Research Day, Toronto, Canada and at the 13th Conference of the International Society of Travel Medicine, Maastricht, the Netherlands.
December 2011) and 31 cases across Canada between 2001 and 2010 (Hong-Xing Wu, personal communication, January 2012). However, HBV infection is a vaccine-preventable disease that is associated with significant morbidity and mortality. Thus, all travelers to HBV-endemic countries are advised to be vaccinated. 3 Three recombinant HBV vaccine products are approved for adults in Canada and are considered interchangeable. 3 The standard HBV vaccination schedule (SVS) consists of three doses given at day 0, 1 month, and 6 months. A rapid schedule is approved with doses given on day 0, 7, and 21 followed by a booster at 1 year.
However, travelers commonly present to travel clinics within 21 days of departure, and are therefore ineligible for the rapid vaccination schedule. For these patients, some physicians offer a two-visit vaccination schedule (TVS) that consists of a double-dose HBV vaccine at day 0 followed by a final single dose in 4 to 12 months. The rationale for the TVS is that it provides patients with the best possible immunity within the limited time available, with a negligible increase in side effects. A double dose of the standard products is used routinely and safely for renal dialysis patients. 2 In addition, a double-dose/double-dose TVS has been shown to be effective in adolescents 11 to 15 years old and has been standard in the school-based vaccination programs in British Columbia since 2001. 8 To date, few studies have explored seroprotection against HBV following a TVS (summarized in Table 1 ). Overall, the evidence is promising that the TVS may be a reasonable alternative to the SVS as the majority of patients in these studies had seroprotective levels of antibodies against HBV surface antigen (anti-HBs) following a TVS. Furthermore, a small study found that a TVS was effective at preventing HBV infection in patients living in a country with high rates of HBV transmission. 13 Thus, there is evidence that a TVS is effective at reducing HBV infection. We sought to assess the seroprotection against HBV using a TVS compared with the SVS and evaluate variables that might influence immunity. In addition, we determined the completion rate of a TVS.
Methods
This was a retrospective chart review, involving three travel clinics in British Columbia, Canada. Clinics 1 and 3 are located in a large urban setting (population > 1,000,000) while clinic 2 is in a small city (population < 1,000,000). Travelers who presented with insufficient time for a SVS, or were unable to return for a SVS prior to their departure, were offered a TVS. The TVS consisted of a double dose of vaccine at day 0 and a single dose in 4 to 12 months. During the second visit, patients were given a requisition for anti-HBs levels, with instructions to be tested in 1 to 6 months. If the anti-HBs serology was less than 10 mIU/mL, the patient was offered another single-dose HBV with repeat serology 1 month later for HBV surface antigen, as well as for anti-HBs and core antigen. If the patient still did not show evidence of immunity, a maximum of two additional doses of vaccine (for a total of six doses received) were offered to attain protective serology, as per the standard protocol with SVS.
This TVS used a single dose for the second visit because preliminary data from British Columbia showed that a single dose was as effective as a double dose (Simon Dobson, personal communication, August 2011). Moreover, there would be no difference in cost to the patient compared with the SVS.
Patients included were adults ≥20 years of age who presented to a travel clinic and desired protection against HBV. The participants should not have received HBV vaccines previously and have no history of HBV disease. Data were analyzed on patients who completed the TVS and had serology drawn according to the protocol. Charts of patients who had serology collected between May 11, 2010 and September 20, 2012 were reviewed for the seroprotection arm of the study.
The vaccines utilized were Recombivax (Merck Kirkland, QC, Canada), Engerix and Twinrix (GlaxoSmithKline Mississauga, ON, Canada). Recombivax has 10 mcg of HBV antigen compared with 20 mcg in Engerix and Twinrix. However, all vaccines are considered interchangeable. 3 Patient age, HBV vaccination dates, brand of vaccine received, and anti-HBs titers information were collected.
Studies indicate that about 96% of people receiving the SVS have an adequate antibody level 1 month after vaccine series completion. 14, 15 We estimated that at least 90% of patients receiving the TVS would produce an adequate antibody level. Thus, the study required 92 patients to have sufficient power to show no difference between the SVS and TVS (given a power of 80% and alpha-level of 5%). Logistic regression was performed to evaluate factors that may influence immunity. 
Results
A total of 117 patients were included for this study. Patient characteristics are shown in Table 2 . Engerix was most commonly used for the first visit (n = 81, 69.2%) while Twinrix was most commonly used for the second visit (n = 71, 60.7%). The most common combination was an initial dose of Engerix boosted with Twinrix (n = 43, 36.8%). The next two most common combinations were Engerix for all doses (n = 32, 27.4%), followed by Twinrix for all doses (n = 23, 19.7%). The median time interval between the two visits was 224 days (interquartile range: 196-275 days).
Seroprotection
Overall 82.9% (97 patients) achieved seroprotection against HBV with the TVS, significantly lower than 96% reported in the literature for the SVS (p < 0.001). Clinic 1 had the highest proportion of patients who developed immunity with the TVS (n = 51, 94.4%), while 40 (75.5%) patients in clinic 2 and 6 (60.0%) in clinic 3 achieved immunity against HBV. Table 3 shows the proportion of patients who were immune to HBV by 10-year-age stratifications and by age greater or less than 50 years.
Factors Influencing Seroprotection
Increasing age tended to be associated with reduced odds of achieving immunity to HBV using the TVS [unadjusted odds ratio (OR) = 0.950, 95% confidence interval (CI): 0.900, 1.002], as shown by logistic regression. This relationship was similar after controlling for the brand of vaccine used (adjusted OR = 0.954, 95% CI: 0.904, 1.008) ( Table 4) .
Vaccines from different manufacturers did not significantly affect seroprotection rates when analyzed by logistic regression. Patients generally received different vaccines for the first and second visits as a result of varying availability of products and the need for hepatitis A virus (HAV) vaccination. There were insufficient numbers of patients who were given the same vaccine products on both visits to do a meaningful comparison.
Completion Rate
In clinics 1 and 2, 528 patients received the double-dose vaccine between October 1, 2009 and September 30, 2010. However, only 172 returned to receive the final dose as advised, resulting in a completion rate of 32.6%. Clinic 1 had a lower completion rate at 23.5% (80/340) versus 48.9% (92/188) at clinic 2. Clinic 1 relied on the patients to book their own second visit. Frequently, but not in a systematic manner, the clinic staff would call the persons to remind them to return for their final dose and have their titers drawn. In contrast, clinic 2 scheduled the follow-up visit at the first visit and reminded patients by telephone, several days prior to their appointment.
Discussion
Overall, we found that about 83% of patients demonstrated immunity against HBV using this TVS. Age was the strongest predictor of vaccine response, consistent with other studies on vaccine effectiveness. 13, 16, 11 This is important as people seen in travel clinics seeking HBV protection may be older than populations seen in other primary care settings. In our experience, about 75% of our patients receiving HBV vaccination were older than 50 years. The proportion of patients under age 50 who achieved seroprotective levels of anti-HBs was similar to results published for the SVS, which report 90-95% of patients produced measurable antibody response. 1, 17 Notably, we also found that 79.5% of patients 50 years and older who received the TVS developed immunity against HBV, exceeding the seroconversion rates described for similar aged patients who received the SVS. Robinson reported that 70% of patients aged 50 to 59 years and 50% of patients aged 60 years and older were immune to HBV. 18 Similarly, Wolters and colleagues found that 33% of participants 60 years and older developed seroprotection against HBV with a SVS using Twinrix. 19 The increased antigen content of a Table 3 Number and proportion of patients who were immune, by age group double-dose HBV vaccine may generate a more robust immune response compared to a single dose in an older individual. Further research in this area would be useful. The proportion of patients with immunity against HBV differed between clinics despite similar age distributions. One possible explanation for this is the different patient demographics. Clinic 1 is in a region with a large Asian immigrant population, and has a carrier rate for HBV as high as 103.2 per 100,000 people in some areas. In comparison, the catchment region for clinic 2 has an HBV carrier rate of 7.9 per 100,000 people. The average HBV carrier rate for British Columbia is 25.2 per 100,000 people. 17 Thus, many of the people who attended clinic 1 may have had pre-existing natural immunity to HBV. In this study, screening for prior infection or immunity was not feasible in the time prior to departure. Instead, the travel physicians relied on patient-supplied history of natural disease or immunization. Clinics 1 and 3 had different seroprotective rates despite having the same catchment population, similar clinic structure, and vaccination techniques. This may be an effect of the small sample size from clinic 3 or unmeasured variables, such as co-morbidities. Unfortunately, relatively little information was collected during the travel medical consultation (compared to a patient's primary care provider) and thus, we were not able to evaluate other hypotheses.
Importantly, completion rates of the TVS were generally low and varied significantly between clinics 1 and 2. Thus, other factors may have contributed to the differences in immunity. Future studies should include baseline serology to identify HBV carriers, as this would help to clarify the true efficacy of the TVS. Additional variables that may influence immunity, such as co-morbidities, could also be evaluated.
We sought to evaluate the "real world" adherence to a TVS. The majority of patients did not return to the travel clinic to complete the TVS. However, patients may have received their final dose from another healthcare provider and therefore, would not be known to have completed the TVS. Nevertheless, the improved completion rate at clinic 2 underscores the importance of a proactive systematic approach for follow-up and the need for continual quality improvement.
We additionally observed that, many persons completed the TVS with more than 12 months between the two doses and still had a high rate of seroconversion to immune titers. Similarly, persons who completed the TVS, but had serology measured more than 6 months later often showed immunity. These people were not captured by our study protocol, but this suggests that the TVS is likely more effective than our retrospective chart review protocol could identify. This supports the highly immunogenic nature of HBV vaccine and great flexibility of immunization schedules. The majority of people who were non-immune after completion of the TVS developed an immune serology following a booster dose. The longevity of the immune response produced by TVS versus SVS in older adults is unclear, but studies on using a TVS in adolescents show that the response remains robust, even 10 years later. 20 Designing a prospective randomized study would help clarify these points.
While this study found evidence for the effectiveness of a TVS in conferring immunity to HBV, it is unclear how well travelers are protected during their trip. Further study exploring when HBV immunity is conferred following the administration of a double-dose HBV vaccine would help inform travel practitioners. Mathematical modeling of B-and T-cell immune responses to HBV vaccine suggests that protection against HBV is likely conferred at the time of the initial dose despite anti-HBs sero-negativity. 21 A subsequent exposure to a booster dose of vaccine or natural exposure to HBV then stimulates antibody production to seroprotective levels. The TVS may therefore be sufficient to protect most travelers against HBV during their trip. Similarly, current HAV vaccines are effective in preventing HAV disease when administered as post-exposure prophylaxis, and by inference, just before exposure, despite a lack of serologically detectible antibody. 22 Hepatitis vaccine effectiveness is likely potentiated by the unusually long incubation period of both HAV and HBV. Studies using novel B-and T-cell immunity markers may be helpful and more specific in determining the quality of immunity against HBV after the initial vaccine dose and likely at an earlier time. 23 Overall, our study adds to the limited number of published studies that a TVS is effective in conferring immunity against HBV. However, there are still gaps in knowledge in the travel clinic setting, such as whether patients are being protected during their travels. Nevertheless, this study is intended to inform clinical decision-making and spur research into alternate vaccination schedules. Given the increase in medical and dental tourism activities, efficient and opportunistic vaccination against HBV remains important. New horizons in HBV vaccination include highly immunogenic TVS products that are currently under development. 24 A head-to-head comparison using double doses of current products versus the newer vaccine products would be valuable to help delineate the role for different products in protecting people from acquiring HBV illness.
